vs

Side-by-side financial comparison of Foghorn Therapeutics Inc. (FHTX) and John Marshall Bancorp, Inc. (JMSB). Click either name above to swap in a different company.

John Marshall Bancorp, Inc. is the larger business by last-quarter revenue ($16.8M vs $9.2M, roughly 1.8× Foghorn Therapeutics Inc.). John Marshall Bancorp, Inc. runs the higher net margin — 36.3% vs -234.3%, a 270.6% gap on every dollar of revenue. Over the past eight quarters, Foghorn Therapeutics Inc.'s revenue compounded faster (35.3% CAGR vs 15.3%).

Foghorn Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing novel therapies targeting the chromatin regulatory system to treat various types of cancer and other severe diseases. It advances a diverse pipeline of targeted drug candidates, conducting internal R&D and strategic partnerships to serve global patient populations.

John Marshall Bancorp, Inc. is a U.S.-based bank holding company that operates through its wholly owned subsidiary John Marshall Bank. It provides a full suite of commercial and consumer banking products including deposit accounts, commercial loans, residential mortgages, and personal financial services, primarily serving retail customers and small-to-mid-sized businesses across the U.S. Mid-Atlantic region.

FHTX vs JMSB — Head-to-Head

Bigger by revenue
JMSB
JMSB
1.8× larger
JMSB
$16.8M
$9.2M
FHTX
Higher net margin
JMSB
JMSB
270.6% more per $
JMSB
36.3%
-234.3%
FHTX
Faster 2-yr revenue CAGR
FHTX
FHTX
Annualised
FHTX
35.3%
15.3%
JMSB

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
FHTX
FHTX
JMSB
JMSB
Revenue
$9.2M
$16.8M
Net Profit
$-21.7M
$6.1M
Gross Margin
Operating Margin
-258.2%
Net Margin
-234.3%
36.3%
Revenue YoY
223.8%
Net Profit YoY
-11.1%
26.8%
EPS (diluted)
$-0.35
$0.43

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
FHTX
FHTX
JMSB
JMSB
Q1 26
$16.8M
Q4 25
$9.2M
$16.4M
Q3 25
$8.2M
$16.3M
Q2 25
$7.6M
$15.4M
Q1 25
$6.0M
$14.6M
Q4 24
$2.9M
$14.3M
Q3 24
$7.8M
$13.8M
Q2 24
$6.9M
$12.6M
Net Profit
FHTX
FHTX
JMSB
JMSB
Q1 26
$6.1M
Q4 25
$-21.7M
$5.9M
Q3 25
$-15.8M
$5.4M
Q2 25
$-17.9M
$5.1M
Q1 25
$-18.8M
$4.8M
Q4 24
$-19.5M
$4.8M
Q3 24
$-19.1M
$4.2M
Q2 24
$-23.0M
$3.9M
Operating Margin
FHTX
FHTX
JMSB
JMSB
Q1 26
Q4 25
-258.2%
47.4%
Q3 25
-226.9%
42.2%
Q2 25
-279.2%
42.7%
Q1 25
-385.0%
42.4%
Q4 24
-840.5%
42.5%
Q3 24
-305.5%
38.8%
Q2 24
-386.6%
39.7%
Net Margin
FHTX
FHTX
JMSB
JMSB
Q1 26
36.3%
Q4 25
-234.3%
36.2%
Q3 25
-194.4%
33.2%
Q2 25
-237.3%
33.1%
Q1 25
-316.4%
32.9%
Q4 24
-682.9%
33.3%
Q3 24
-244.9%
30.7%
Q2 24
-333.6%
30.9%
EPS (diluted)
FHTX
FHTX
JMSB
JMSB
Q1 26
$0.43
Q4 25
$-0.35
$0.41
Q3 25
$-0.25
$0.38
Q2 25
$-0.28
$0.36
Q1 25
$-0.30
$0.34
Q4 24
$-0.23
$0.33
Q3 24
$-0.31
$0.30
Q2 24
$-0.45
$0.27

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
FHTX
FHTX
JMSB
JMSB
Cash + ST InvestmentsLiquidity on hand
$80.9M
$150.2M
Total DebtLower is stronger
Stockholders' EquityBook value
$-108.5M
$268.1M
Total Assets
$198.1M
$2.4B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
FHTX
FHTX
JMSB
JMSB
Q1 26
$150.2M
Q4 25
$80.9M
$130.0M
Q3 25
$89.3M
$163.6M
Q2 25
$72.6M
$116.9M
Q1 25
$61.0M
$169.1M
Q4 24
$55.5M
$122.5M
Q3 24
$57.7M
$177.2M
Q2 24
$138.9M
$182.6M
Total Debt
FHTX
FHTX
JMSB
JMSB
Q1 26
Q4 25
$80.9M
Q3 25
$80.9M
Q2 25
$80.8M
Q1 25
$80.8M
Q4 24
$80.8M
Q3 24
$80.8M
Q2 24
$24.7M
Stockholders' Equity
FHTX
FHTX
JMSB
JMSB
Q1 26
$268.1M
Q4 25
$-108.5M
$265.6M
Q3 25
$-89.7M
$259.7M
Q2 25
$-76.7M
$253.7M
Q1 25
$-61.7M
$253.0M
Q4 24
$-45.5M
$246.6M
Q3 24
$-28.3M
$243.1M
Q2 24
$-14.3M
$235.3M
Total Assets
FHTX
FHTX
JMSB
JMSB
Q1 26
$2.4B
Q4 25
$198.1M
$2.3B
Q3 25
$205.0M
$2.3B
Q2 25
$226.2M
$2.3B
Q1 25
$258.7M
$2.3B
Q4 24
$284.0M
$2.2B
Q3 24
$308.4M
$2.3B
Q2 24
$328.6M
$2.3B
Debt / Equity
FHTX
FHTX
JMSB
JMSB
Q1 26
Q4 25
0.30×
Q3 25
0.31×
Q2 25
0.32×
Q1 25
0.32×
Q4 24
0.33×
Q3 24
0.33×
Q2 24
0.11×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
FHTX
FHTX
JMSB
JMSB
Operating Cash FlowLast quarter
$-22.3M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
0.0%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
FHTX
FHTX
JMSB
JMSB
Q1 26
Q4 25
$-22.3M
$22.6M
Q3 25
$-18.9M
$1.2M
Q2 25
$-21.0M
$7.5M
Q1 25
$-24.0M
$7.0M
Q4 24
$-24.5M
$17.3M
Q3 24
$-21.0M
$1.4M
Q2 24
$-25.5M
$10.2M
Free Cash Flow
FHTX
FHTX
JMSB
JMSB
Q1 26
Q4 25
$22.0M
Q3 25
$1.2M
Q2 25
$-21.0M
$7.4M
Q1 25
$-24.0M
$6.6M
Q4 24
$-25.0M
$16.8M
Q3 24
$-21.3M
$1.3M
Q2 24
$-25.6M
$10.1M
FCF Margin
FHTX
FHTX
JMSB
JMSB
Q1 26
Q4 25
134.7%
Q3 25
7.3%
Q2 25
-278.2%
47.8%
Q1 25
-403.2%
45.3%
Q4 24
-875.3%
116.9%
Q3 24
-273.0%
9.5%
Q2 24
-371.0%
80.1%
Capex Intensity
FHTX
FHTX
JMSB
JMSB
Q1 26
Q4 25
0.0%
3.4%
Q3 25
0.0%
0.2%
Q2 25
0.3%
1.0%
Q1 25
0.5%
2.3%
Q4 24
16.8%
3.4%
Q3 24
4.0%
0.8%
Q2 24
0.2%
0.4%
Cash Conversion
FHTX
FHTX
JMSB
JMSB
Q1 26
Q4 25
3.82×
Q3 25
0.23×
Q2 25
1.48×
Q1 25
1.45×
Q4 24
3.61×
Q3 24
0.33×
Q2 24
2.60×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

FHTX
FHTX

Segment breakdown not available.

JMSB
JMSB

Net Interest Income$16.5M98%
Noninterest Income$284.0K2%

Related Comparisons